Loading
POU2AF1 (POU domain class 2-associating factor 1) is a protein that switches other genes on and off. The public catalogues list it as a biomarker and a fusion partner, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Lung cancer, Skin cancer and 1 more.
Transcriptional coactivator that specifically associates with either POU2F1/OCT1 or POU2F2/OCT2. It boosts the POU2F1/OCT1 mediated promoter activity and to a lesser extent, that of POU2F2/OCT2. It recognises the POU domains of POU2F1/OCT1 and POU2F2/OCT2.
CIViC holds 1 clinical evidence item and 0 assertions across 1 variant. Open Targets scores its association with cancer at 0.59 (direct and indirect evidence; datatypes literature 0.46, genetic association 0.00, somatic mutation 0.95).
In plain words · POU2AF1 (POU domain class 2-associating factor 1) is a protein that switches other genes on and off. The public catalogues list it as a biomarker and a fusion partner, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Lung cancer, Skin cancer and 1 more.
POU2AF1 (POU domain class 2-associating factor 1) is a protein that switches other genes on and off. The public catalogues list it as a biomarker and a fusion partner, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Lung cancer, Skin cancer and 1 more.
Transcriptional coactivator that specifically associates with either POU2F1/OCT1 or POU2F2/OCT2. It boosts the POU2F1/OCT1 mediated promoter activity and to a lesser extent, that of POU2F2/OCT2.
No product in this corpus aims at POU2AF1 yet. Transcription factors have no pocket to plug, so drugs either degrade them or block the partner protein they need to dock on DNA.
Tumour-specific alteration: the catalogues call it a fusion partner (UniProt records a translocation); what a medicine would aim at or exploit is the altered form or its loss, absent from normal cells; no corpus medicine is aimed at it yet. HPA POU2AF1: RNA group enriched (intestine 41 nTPM, lymphoid tissue 112 nTPM, stomach 1 38 nTPM); blood lineage lineage enriched (B-cells 34 nTPM); high antibody staining in 3 normal tissues; highest cancer staining melanoma (4 of 11 high). Distribution: 3 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Lymphoma, Lung cancer (all types), Skin cancer (all types)); Open Targets associates it with 0 specific cancer types at or above 0.5. (Rule 6 of scripts/fetch-target-specificity.ts.)
Sources: UniProt Q16633; CIViC gene POU2AF1; Human Protein Atlas POU2AF1 tissue; Open Targets ENSG00000110777 associations
First described 1995. Earliest sequence paper UniProt cites for the protein: Strubin et al, Cell, 1995, "OBF-1, a novel B cell-specific coactivator that stimulates immunoglobulin promoter activity through association with octamer-binding proteins". Source.
Sources: HGNC HGNC:9211 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q16633 (protein name, function text, keywords and locations (REST API)); CIViC gene POU2AF1 (1 evidence items, 0 assertions, 1 variants; diseases: Diffuse Large B-cell Lymphoma (GraphQL API, CC0)); Open Targets ENSG00000110777 (association with cancer (MONDO_0004992) 0.59; per-cancer scores at or above 0.5: non-Hodgkin lymphoma 0.54, skin cancer 0.50, lung cancer 0.51 (GraphQL API, CC0))
Transcriptional coactivator that specifically associates with either POU2F1/OCT1 or POU2F2/OCT2. It boosts the POU2F1/OCT1 mediated promoter activity and to a lesser extent, that of POU2F2/OCT2. It recognises the POU domains of POU2F1/OCT1 and POU2F2/OCT2. It is essential for the response of B-cells to antigens and required for the formation of germinal centres. Regulates IL6 expression in B cells as POU2F2/OCT2 coactivator. Location: Nucleus (UniProt). Locus 11q23.1 (HGNC).
RNA: group enriched (intestine 41 nTPM, lymphoid tissue 112 nTPM, stomach 1 38 nTPM), detected in many normal tissues. Blood: lineage enriched (B-cells 34 nTPM).
Medium: Bone marrow, Spleen, Testis.
Medium only: endometrial cancer, liver cancer, ovarian cancer.
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"POU2AF1" OR ABSTRACT:"POU2AF1" OR TITLE:"POU class 2 homeobox associating factor 1" OR ABSTRACT:"POU class 2 homeobox associating factor 1" OR TITLE:"POU domain class 2-associating factor 1" OR ABSTRACT:"POU domain class 2-associating factor 1" OR TITLE:"OBF1" OR ABSTRACT:"OBF1" OR TITLE:"BOB1" OR ABSTRACT:"BOB1" OR TITLE:"OCA-B" OR ABSTRACT:"OCA-B") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about POU2AF1, not a curated reading list.